Redwood Pharma AB
Redwood Pharma AB engages in the development of ophthalmic drugs for medical needs in Sweden. Its lead development product is RP101, an eye drop that treats severe chronic dry eye disease in post-menopausal women; and RP501, a next generation smart hydrogel medical device for the treatment of mild dry eye. The company was founded in 2012 and is headquartered in Stockholm, Sweden.
Redwood Pharma AB (REDW) - Net Assets
Latest net assets as of March 2024: Skr10.19 Million SEK
Based on the latest financial reports, Redwood Pharma AB (REDW) has net assets worth Skr10.19 Million SEK as of March 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr11.68 Million) and total liabilities (Skr1.49 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr10.19 Million |
| % of Total Assets | 87.27% |
| Annual Growth Rate | 76.77% |
| 5-Year Change | 11.79% |
| 10-Year Change | N/A |
| Growth Volatility | 153.88 |
Redwood Pharma AB - Net Assets Trend (2014–2023)
This chart illustrates how Redwood Pharma AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Redwood Pharma AB (2014–2023)
The table below shows the annual net assets of Redwood Pharma AB from 2014 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | Skr13.58 Million | -11.24% |
| 2022-12-31 | Skr15.30 Million | -3.71% |
| 2021-12-31 | Skr15.89 Million | +124.49% |
| 2020-12-31 | Skr7.08 Million | -41.73% |
| 2019-12-31 | Skr12.15 Million | -5.84% |
| 2018-12-31 | Skr12.90 Million | +355.63% |
| 2017-12-31 | Skr2.83 Million | -75.82% |
| 2016-12-31 | Skr11.71 Million | +13903.13% |
| 2015-12-31 | Skr-84.87K | -205.24% |
| 2014-12-31 | Skr80.64K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Redwood Pharma AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 18513.3% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr13.27 Million | 97.68% |
| Other Components | Skr4.93 Million | 36.32% |
| Total Equity | Skr13.58 Million | 100.00% |
Redwood Pharma AB Competitors by Market Cap
The table below lists competitors of Redwood Pharma AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
NATIONAL AUSTRAL BK
MU:NAL
|
$277.38K |
|
STATOIL
MU:DNQ
|
$277.42K |
|
Synel M.L.L Payway Ltd
TA:SNEL
|
$277.66K |
|
Trendline
TA:TREN
|
$277.77K |
|
MICHELIN NOM. EO -50
F:MCHA
|
$277.13K |
|
ARK Venture Fund
NMFQS:ARKVX
|
$277.12K |
|
OSAKA GAS
BE:OSA
|
$277.04K |
|
DOUGLAS DYNAMICS
BE:5D4
|
$277.01K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Redwood Pharma AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 15,304,146 to 13,584,501, a change of -1,719,645 (-11.2%).
- Net loss of 14,185 reduced equity.
- Other comprehensive income decreased equity by 928,000.
- Other factors decreased equity by 777,460.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-14.18K | -0.1% |
| Other Comprehensive Income | Skr-928.00K | -6.83% |
| Other Changes | Skr-777.46K | -5.72% |
| Total Change | Skr- | -11.24% |
Book Value vs Market Value Analysis
This analysis compares Redwood Pharma AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | Skr0.00 | Skr1.19 | x |
| 2016-12-31 | Skr0.68 | Skr1.19 | x |
| 2017-12-31 | Skr0.10 | Skr1.19 | x |
| 2018-12-31 | Skr0.33 | Skr1.19 | x |
| 2019-12-31 | Skr24.61 | Skr1.19 | x |
| 2020-12-31 | Skr14.08 | Skr1.19 | x |
| 2021-12-31 | Skr23.97 | Skr1.19 | x |
| 2022-12-31 | Skr33.24 | Skr1.19 | x |
| 2023-12-31 | Skr5118.50 | Skr1.19 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Redwood Pharma AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -0.10%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.07x
- Recent ROE (-0.10%) is above the historical average (-141.67%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 0.10% | 0.00% | 0.00x | 1.34x | Skr-7.98K |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | Skr-149.29K |
| 2016 | -74.59% | 0.00% | 0.00x | 1.18x | Skr-9.91 Million |
| 2017 | -678.43% | 0.00% | 0.00x | 3.21x | Skr-19.50 Million |
| 2018 | -108.25% | 0.00% | 0.00x | 1.32x | Skr-15.26 Million |
| 2019 | -131.70% | 0.00% | 0.00x | 1.19x | Skr-17.22 Million |
| 2020 | -205.18% | 0.00% | 0.00x | 1.81x | Skr-15.24 Million |
| 2021 | -133.39% | 0.00% | 0.00x | 1.33x | Skr-22.79 Million |
| 2022 | -85.15% | 0.00% | 0.00x | 1.19x | Skr-14.56 Million |
| 2023 | -0.10% | 0.00% | 0.00x | 1.07x | Skr-1.37 Million |
Industry Comparison
This section compares Redwood Pharma AB's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $60,327,288
- Average return on equity (ROE) among peers: -132.31%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Redwood Pharma AB (REDW) | Skr10.19 Million | 0.10% | 0.15x | $277.13K |
| 2cureX AB (2CUREX) | $20.24 Million | -15.50% | 0.13x | $1.38 Million |
| Abliva AB (ABLI) | $63.04 Million | -23.59% | 0.13x | $46.60 Million |
| Ascelia Pharma AB (publ) (ACE) | $180.86 Million | -72.56% | 0.21x | $25.35 Million |
| AcouSort AB (ACOU) | $20.11 Million | -65.68% | 1.12x | $4.82 Million |
| Active Biotech AB (ACTI) | $162.30 Million | -107.35% | 0.93x | $3.55 Million |
| Alzinova AB (ALZ) | $29.39 Million | -8.53% | 0.08x | $4.19 Million |
| AlzeCure Pharma (ALZCUR) | $110.75 Million | -64.44% | 0.06x | $12.56 Million |
| Annexin Pharmaceuticals AB (ANNX) | $20.64 Million | -216.80% | 0.22x | $4.92 Million |
| Alligator Bioscience AB (ATORX) | $6.86 Million | -748.65% | 15.13x | $723.60K |
| Biosergen AS (BIOSGN) | $-10.92 Million | 0.00% | 0.00x | $2.76 Million |